vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and SciSparc Ltd. (SPRC). Click either name above to swap in a different company.
SciSparc Ltd. is the larger business by last-quarter revenue ($461.0K vs $410.0K, roughly 1.1× Solowin Holdings, Ltd.).
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in the neurological, psychiatric, and gastrointestinal disorder segments. It operates across global biotech markets, leveraging proprietary cannabinoid-based formulation technologies to advance its pipeline of therapeutic candidates.
AXG vs SPRC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $461.0K |
| Net Profit | — | $-9.4M |
| Gross Margin | — | 78.1% |
| Operating Margin | -34.1% | -588.5% |
| Net Margin | — | -2041.6% |
| Revenue YoY | — | -45.1% |
| Net Profit YoY | — | -155.8% |
| EPS (diluted) | — | $17.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $461.0K | ||
| Q4 24 | — | $466.0K | ||
| Q3 24 | $410.0K | — | ||
| Q2 24 | — | $840.0K | ||
| Q2 23 | — | $2.0M |
| Q2 25 | — | $-9.4M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-3.7M | ||
| Q2 23 | — | $-2.9M |
| Q2 25 | — | 78.1% | ||
| Q4 24 | — | 6.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 56.4% | ||
| Q2 23 | — | 74.2% |
| Q2 25 | — | -588.5% | ||
| Q4 24 | — | -813.1% | ||
| Q3 24 | -34.1% | — | ||
| Q2 24 | — | -419.9% | ||
| Q2 23 | — | -150.5% |
| Q2 25 | — | -2041.6% | ||
| Q4 24 | — | -813.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -438.0% | ||
| Q2 23 | — | -148.7% |
| Q2 25 | — | $17.92 | ||
| Q4 24 | — | $-8.82 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $35.70 | ||
| Q2 23 | — | $10.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $1.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $-81.0K |
| Total Assets | $13.1M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $1.5M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | — | $252.0K | ||
| Q2 23 | — | $2.1M |
| Q2 25 | — | $-81.0K | ||
| Q4 24 | — | $8.9M | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | — | $8.7M | ||
| Q2 23 | — | $6.8M |
| Q2 25 | — | $5.1M | ||
| Q4 24 | — | $10.3M | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | — | $10.5M | ||
| Q2 23 | — | $9.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-1.9M |
| Free Cash FlowOCF − Capex | $-1.6M | — |
| FCF MarginFCF / Revenue | -392.9% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-1.9M | ||
| Q4 24 | — | $-2.9M | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | $-2.2M | ||
| Q2 23 | — | $-3.2M |
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | $-2.2M | ||
| Q2 23 | — | — |
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -392.9% | — | ||
| Q2 24 | — | -261.7% | ||
| Q2 23 | — | — |
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | — | 0.1% | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
